← back to search

Pierre Grammond

Université Claude Bernard Lyon 1 · FR
Area of research
Pathology and Forensic Medicine · Neurology
Research interest
Research interests include Medicine, Multiple sclerosis, Internal medicine, Cohort, Expanded Disability Status Scale, and Fingolimod.
h-index
citations
2,047
works
16
NIH funding
primary concept
email

Recent publications

Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis
JAMA Neurology 2023cited by 50position: middledoi
Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis
Neurology 2022cited by 46position: middledoi
Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression
Computer Methods and Programs in Biomedicine 2021cited by 42position: middledoi
Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple Sclerosis
Neurology 2021cited by 29position: middledoi
Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study
The Lancet Neurology 2020cited by 426position: middledoi
Early clinical markers of aggressive multiple sclerosis
Brain 2020cited by 59position: middledoi
Delay from treatment start to full effect of immunotherapies for multiple sclerosis
Brain 2020cited by 39position: middledoi
Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy
Journal of the Neurological Sciences 2018cited by 35position: middledoi
Towards personalized therapy for multiple sclerosis: prediction of individual treatment response
Brain 2017cited by 146position: middledoi
Defining secondary progressive multiple sclerosis
Brain 2016cited by 410position: middledoi
Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study
Journal of Neurology Neurosurgery & Psychiatry 2016cited by 98position: middledoi
Contribution of different relapse phenotypes to disability in multiple sclerosis
Multiple Sclerosis Journal 2016cited by 39position: middledoi
Defining reliable disability outcomes in multiple sclerosis
Brain 2015cited by 237position: middledoi
Switch to natalizumab versus fingolimod in active relapsing–remitting multiple sclerosis
Annals of Neurology 2014cited by 158position: middledoi
Sex as a determinant of relapse incidence and progressive course of multiple sclerosis
Brain 2013cited by 193position: middledoi
Increasing age at disability milestones among MS patients in the MSBase Registry
Journal of the Neurological Sciences 2012cited by 40position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Raymond Hupperts · University of Oslo2 papers (2016–2018)Tim Spelman · Burnet Institute2 papers (2016–2018)Jeannette Lechner‐Scott · Newcastle University2 papers (2016–2018)María Trojano · University of Bari Aldo Moro2 papers (2016–2018)Helmut Butzkueven · The Alfred Hospital2 papers (2016–2018) · 2 papers (2016–2018)Alessandra Lugaresi · University of Ferrara2 papers (2016–2018)Raed Alroughani · Neurology, Inc2 papers (2016–2018)Pierre Duquette · Monash University2 papers (2016–2018)François Grand’Maison · Université Claude Bernard Lyon 12 papers (2016–2018)Ilya Kister · Multiple Sclerosis Center Of Northeastern New York2 papers (2016–2018)Francesco Patti · Université Claude Bernard Lyon 11 papers (2018–2018)Patrizia Sola · Azienda Ospedaliero-Universitaria di Modena1 papers (2018–2018)Michael Barnett · The University of Sydney1 papers (2016–2016)Claudio Solaro · Gene Therapy Laboratory1 papers (2018–2018)Guillermo Izquierdo · Université Claude Bernard Lyon 11 papers (2018–2018)Diana Ferraro · Azienda Ospedaliero-Universitaria di Modena1 papers (2018–2018)Murat Terzi · Université Claude Bernard Lyon 11 papers (2018–2018)Cavit Boz · Université Claude Bernard Lyon 11 papers (2018–2018) · 1 papers (2016–2016)